Literature DB >> 6144283

Blepharospasm: demographic and clinical survey of 250 patients.

J Jankovic, J Orman.   

Abstract

The pathophysiologic mechanisms of blepharospasm are poorly understood and the condition is often misdiagnosed. In an attempt to improve our understanding of blepharospasm, 250 patients with blepharospasm were surveyed. This heretofore largest reported series of blepharospasm patients reveals findings of clinical and demographic interest. For example, there is a 3 to 1 female preponderance, the age of onset is in the fifth or sixth decade of life in two-thirds of patients, the onset is usually gradual with progressive deterioration and involuntary spasms of other portions of face and body. Although specific ocular abnormalities may predispose a patient to blepharospasm, in most cases the blepharospasm is a form of focal dystonia often associated with other involuntary movements and neurologic abnormalities. Increased awareness of blepharospasm among primary care physicians as well as ophthalmologists, neurologists, psychiatrists, and other specialists should lead to early recognition and management of this disabling condition.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144283

Source DB:  PubMed          Journal:  Ann Ophthalmol        ISSN: 0003-4886


  24 in total

1.  Clinical features of patients with blepharospasm: a report of 240 patients.

Authors:  E L Peckham; G Lopez; E A Shamim; S Pirio Richardson; S Sanku; R Malkani; M Stacy; P Mahant; A Crawley; A Singleton; M Hallett
Journal:  Eur J Neurol       Date:  2011-03       Impact factor: 6.089

2.  Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.

Authors:  P Roggenkämper; W H Jost; K Bihari; G Comes; S Grafe
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

3.  Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.

Authors:  A R Bentivoglio; A Fasano; T Ialongo; F Soleti; S Lo Fermo; A Albanese
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

Review 4.  Secondary blepharospasm associated with structural lesions of the brain.

Authors:  M A Khooshnoodi; S A Factor; H A Jinnah
Journal:  J Neurol Sci       Date:  2013-06-06       Impact factor: 3.181

5.  Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with Blepharospasm.

Authors:  Francisco Vivancos-Matellano; Ana Rodríguez-Sanz; Yolanda Herrero-Infante; Javier Mascías-Cadavid
Journal:  Neuroophthalmology       Date:  2018-11-26

6.  Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story.

Authors:  Anna Rita Bentivoglio; Tàmara Ialongo; Francesco Bove; Francesca De Nigris; Alfonso Fasano
Journal:  Neurol Sci       Date:  2011-06-28       Impact factor: 3.307

Review 7.  Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin.

Authors:  S P Kraft; A E Lang
Journal:  CMAJ       Date:  1988-11-01       Impact factor: 8.262

8.  Videonystagmography as a tool to assess blepharospasm before and after botulinum toxin injection.

Authors:  Guillaume Casse; Jean-Paul Adenis; Jean-Pierre Sauvage; Pierre-Yves Robert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-26       Impact factor: 3.117

Review 9.  Hysterical symptoms in ophthalmology.

Authors:  M Weller; P Wiedemann
Journal:  Doc Ophthalmol       Date:  1989-09       Impact factor: 2.379

10.  Blepharospasm: a review of 264 patients.

Authors:  F Grandas; J Elston; N Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.